rapivab
rapivab: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| BIOCRYST PHARMACEUTICALS INC (BCRX) | Approved |
FDA Decisions
Frequently asked questions
Who is developing rapivab?
rapivab is being developed by BIOCRYST PHARMACEUTICALS INC.
What is rapivab's latest FDA decision?
The most recent tracked FDA decision for rapivab is Approval for 1 INDICATIONS AND USAGE RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days. RAPIVAB is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than two days. ( 1 ) Limitations of Use : Efficacy based on clinical trials in which the predominant influenza virus type was influenza A;, dated December 19, 2014.
Get deeper analysis on rapivab
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis